Browse our collection of papers in
Astrazeneca (AZN)
C/HR/1184. An examination of graduate opportunities in the current job market
- WORDS:
- 1650
- DATE:
- 2011
- PRICE:
- 19.99 GBP
This paper examines the graduate opportunities available in the current job market. The companies that are focused on include PwC, NHS, British Heart Foundation, Stay (homeless charity), Astra Zeneca and Alexander Chartered Accountants. The expectations of employers and graduates are discussed, and the paper then summarises the general employment trends in the sectors discussed. Opportunities for recent graduates are evaluated, and the skills that are expected of graduates in the job market are outlined. Before conclusions are made, the paper conducts personal analysis.
KEYWORDS: Graduate, graduate opportunities, job market, PwC, PriceWaterHouseCoopers, NHS, British Heart Foundation, Stay, Astra Zeneca, Alexander Chartered Accountants,
C/B/4253. PESTEL, Porter's 5 Forces, SWOT and Value Chain analyses of UBS
- WORDS:
- 3750
- DATE:
- 2011
- PRICE:
- 39.99 GBP
This paper presents a comprehensive analysis of UBS. Firstly the paper presents an overview of UBS followed by PESTEL analysis which identifies the Political, Economic, Social, Technological, Environmental and Legal aspects of business environments. Porter’s Five Forces analysis is provided, discussing the competitiveness of the industry. SWOT analysis is used to evaluate the strengths, weaknesses, opportunities and threats to UBS. The paper also consists of Value Chain analysis looking at the key activities of UBS.
KEYWORDS: PEST, PESTEL, PESTLE, SWOT, Porter, 5 forces, TOWS, Value Chain, UBS,
C/B/4252. PESTEL, Porter's 5 Forces, SWOT and Value Chain analyses of AstraZeneca
- WORDS:
- 3000
- DATE:
- 2011
- PRICE:
- 39.99 GBP
This paper presents a comprehensive analysis of AstraZeneca. Firstly the paper presents an overview of AstraZeneca followed by PESTEL analysis which identifies the Political, Economic, Social, Technological, Environmental and Legal aspects of business environments. Porter’s Five Forces analysis is provided, discussing the competitiveness of the industry. SWOT analysis is used to evaluate the strengths, weaknesses, opportunities and threats to AstraZeneca. The paper also consists of Value Chain analysis looking at the key activities of AstraZeneca.
KEYWORDS: PEST, PESTEL, PESTLE, SWOT, Porter, 5 forces, TOWS, Value Chain, AstraZeneca,
C/B/4251. Porter's 5 Forces analysis of AstraZeneca
- WORDS:
- 900
- DATE:
- 2011
- PRICE:
- 9.99 GBP
This paper analyses AstraZeneca, using Porter’s Five Forces analysis. Firstly an overview of the company is presented. Porter’s 5 forces analysis concentrates on the bargaining power of customers, bargaining power of suppliers, threat of new entrants, threat of substitute products, and intensity of competitive rivalry affecting AstraZeneca.
KEYWORDS: Porter, 5 forces, five forces, AstraZeneca,
C/B/4250. PESTEL and Porter's 5 Forces analyses of AstraZeneca
- WORDS:
- 2000
- DATE:
- 2011
- PRICE:
- 29.99 GBP
This paper critically analyses AstraZeneca, providing an overview of the company followed by PESTEL and Porter’s Five Forces analyses. The PESTEL analysis assesses Political, Economic, Social, Technological, Environmental and Legal factors affecting AstraZeneca. Porter's 5 Forces analysis discusses the bargaining power of customers, bargaining power of suppliers, threat of new entrants, threat of substitute products, and intensity of competitive rivalry of AstraZeneca.
KEYWORDS: PEST, PESTEL, PESTLE, Porter, 5 forces, five forces, AstraZeneca,
C/B/4249. Value chain analysis of AstraZeneca
- WORDS:
- 1100
- DATE:
- 2011
- PRICE:
- 19.99 GBP
This paper presents an overview of AstraZeneca, using Value Chain Analysis. This is a management tool used to identify key activities within an organisation which forms its value chain: Inbound logistics, Operations, outbound logistics, marketing and sales, service, procurements, human resource management, technology development, and firm infrastructure.
KEYWORDS: Value Chain, Inbound logistics, Operations, outbound logistics, marketing and sales, service, procurements, human resource management, technology development and firm infrastructure, AstraZeneca,
C/B/4248. SWOT and Value Chain Analyses of AstraZeneca
- WORDS:
- 1400
- DATE:
- 2011
- PRICE:
- 19.99 GBP
This paper provides an overview of AstraZeneca, followed by a SWOT analysis which evaluates its strengths, weaknesses, opportunities and threats. A Value Chain Analysis of AstraZeneca is conducted to outline Inbound logistics, Operations, outbound logistics, marketing and sales, service, procurements, human resource management, technology development, and firm infrastructure.
KEYWORDS: SWOT, TOWS, Value Chain, Inbound logistics, Operations, outbound logistics, marketing and sales, service, procurements, human resource management, technology development and firm infrastructure, AstraZeneca,
C/B/4247. SWOT analysis of AstraZeneca
- WORDS:
- 600
- DATE:
- 2011
- PRICE:
- 9.99 GBP
This paper evaluates AstraZeneca, using a detailed SWOT analysis. This analysis is conducted to audit AstraZeneca and its environment, and focuses on the strengths, weaknesses, opportunities and threats of AstraZeneca.
KEYWORDS: SWOT, TOWS, AstraZeneca,
C/B/4246. PESTEL and SWOT analyses of AstraZeneca
- WORDS:
- 1700
- DATE:
- 2011
- PRICE:
- 19.99 GBP
This paper provides PESTEL and SWOT analyses of AstraZeneca. Firstly the paper gives an overview of AstraZeneca. Secondly the PESTEL analysis of AstraZeneca is provided identifying Political, Economic, Social, Technological, Environmental and Legal factors affecting AstraZeneca. Lastly the paper outlines SWOT analysis identifying strengths, weaknesses, opportunities and threats of AstraZeneca.
KEYWORDS: PESTEL, PEST, SWOT, TOWS, AstraZeneca,
C/B/4245. PESTEL analysis of AstraZeneca
- WORDS:
- 1450
- DATE:
- 2011
- PRICE:
- 19.99 GBP
This paper presents an overview of AstraZeneca using PESTEL analysis, which identifies the Political, Economic, Social, Technological, Environmental and Legal factors affecting AstraZeneca.
KEYWORDS: PEST, PESTEL, PESTLE, AstraZeneca,
C/B/4244. Strategic Analysis of AstraZeneca
- WORDS:
- 2250
- DATE:
- 2011
- PRICE:
- 29.99 GBP
This paper analyses AstraZeneca. The paper consists of an overview of AstraZeneca, followed by PESTEL analysis, which identifies the Political, Economic, Social, Technological, Environmental and Legal factors of the company. SWOT analysis is used to evaluate the strengths, weaknesses, opportunities and threats to AstraZeneca. Porter's 5 Forces analysis of AstraZeneca is presented, discussing the bargaining power of customers, bargaining power of suppliers, threat of new entrants, threat of substitute products, and intensity of competitive rivalry affecting AstraZeneca.
KEYWORDS: PEST, PESTEL, PESTLE, SWOT, Porter, 5 forces, TOWS, AstraZeneca,
C/F/1204. Financial analysis of GlaxoSmithKline and AstraZeneca
- WORDS:
- 2600
- DATE:
- 2011
- PRICE:
- 29.99 GBP
The paper examines the financial performance of two pharmaceutical companies, GlaxoSmithKline (GSK) and AstraZeneca (AZN) conducting their ratio analysis for 2009 and comparing their financial indices on the basis of the analysis. Recommendations are suggested to the companies’ management and investors.
KEYWORDS: Financial analysis, financial ratios, GlaxoSmithKline, GSK, AstraZeneca, AZN,
S/B/621. Strategic analysis of AstraZeneca PLC
- WORDS:
- 3400
- DATE:
- 2011
- PRICE:
- 39.99 GBP
The paper examines the performance of the pharmaceutical company AstraZeneca (AZN) assessing their mission statement and conducting analysis of the company along the lines of PEST, Porter’s Five Forces and SWOT models.
KEYWORDS: Strategic analysis, AstraZeneca, PEST, Porter’s Five Forces, SWOT,
C/B/2998. Competitive environment evaluation of AstraZeneca
- WORDS:
- 1950
- DATE:
- 2010
- PRICE:
- 19.99 GBP
This paper aims to analyse AstraZeneca, a UK-based pharmaceutical firm in order to understand its competitive environment. The paper begins by providing an overview of the company, followed by a Porter’s Five Forces analysis. The competitive environment and the evolution of AstraZeneca’s business strategies are also evaluated by use of Porter’s generic strategies. The resources and capabilities of the company are discussed, and the paper concludes by summarising and analysing the results from the analyses.
KEYWORDS: AstraZeneca, Pharmaceutical, competitive environment, Porter’s five forces, Porter’s generic strategies, resources, capability,
C/F/766. Financial performance evaluation of Astra Zeneca
- WORDS:
- 1200
- DATE:
- 2010
- PRICE:
- 19.99 GBP
The paper looks at the financial performance of the UK pharmaceutical company Astra Zeneca during 2007-2008 presenting their ratio analysis and evaluating the company’s financial performance along the lies of their sales, profitability, etc.
KEYWORDS: Financial evaluation, ratio analysis, Astra Zeneca,
C/F/560. Strategic Financial Analysis of AstraZeneca and GlaxoSmithKline
- WORDS:
- 3100
- DATE:
- 2009
- PRICE:
- 39.99 GBP
The paper examines the factors that affected the financial performance of AstraZeneca (AZN) and GlaxoSmithKline (GSK) giving particular focus to the analysis of the product portfolio and recent developments in the pharmaceutical industry. An overview of the companies’ ratios over 2004-2008 is provided suggesting recommendations for the investors.
KEYWORDS: GlaxoSmithKline, GSK, AstraZeneca, AZN, pharmaceutical industry,
C/C/140. Feasibility Study: Digital Converter for Sales Force in AstraZeneca
- WORDS:
- 3500
- DATE:
- 2009
- PRICE:
- 39.99 GBP
The paper examines the feasibility of the automation of conversion of handwritten sales call data from the sales force of the pharmaceutical company AstraZeneca into digital formats. The company’s profile is presented arguing that information system (IS) development can create an effective and efficient sales force that is a source of competitive advantage.
KEYWORDS: AstraZeneca, Information system, Pharmaceutical, Sales Force,
C/F/278. AstraZeneca and GlaxoSmithKline share price performance valuation
- WORDS:
- 1300
- DATE:
- 2008
- PRICE:
- 19.99 GBP
The paper examines the factors that affected the share prices of AstraZeneca and GlaxoSmithKline, placing particular focus on the Company announcement published in the London Stock Exchange. A short overview of the company ratios is given suggesting recommendations for investors.
KEYWORDS: GlaxoSmithKline, AstraZeneca, pharmaceuticals,
C/B/587. AstraZeneca: Strategy Evaluation
- WORDS:
- 1400
- DATE:
- 2007
- PRICE:
- 19.99 GBP
AstraZeneca Plc, a leading global pharmaceutical company, specialises in cardiovascular, gastrointestinal, infection, neuroscience, oncological and respiratory therapies. AstraZeneca's key products such as Nexium, Seroquel, Crestor, Arimidex, and Symbicort achieved good sales growth for the third quarter of 2006 in a highly competitive drug making sector. Yet the Company's global sales ranks fourth behind GlaxoSmithKline, Sanofi-Aventis and Novartis. Issues raised in this report denotes a critical dimension that may weaken or strengthen AstraZeneca's position in taking advantage of the opportunities occurring and key developments expected in the pharmaceutical industry in five years from now.
KEYWORDS: AstraZeneca, Strategy, Pharmaceutical Industry, Drug Prescription Sector,
C/B/436. AstraZeneca: Strategic Analysis
- WORDS:
- 2500
- DATE:
- 2006
- PRICE:
- 29.99 GBP
The report provides a strategic analysis for one of the world's well known pharmaceutical companies, AstraZeneca. The report has been divided into three basic parts: external environment analysis, internal environment analysis and options development. The external environment analysis has been provided with the help of PEST, Industry Lifecycle and Porter's Five Forces analyses. The internal environment analysis has been provided by using value chain and hierarchy of resources of the company. The implications of these have been used to develop strategic options with the scenario planning process. The evaluations of these strategic options have also been provided by suitability, acceptability and feasibility indicators.
KEYWORDS: AstraZeneca, PEST, Porters Five Forces, Resources, Strategy, Scenario Planning,
P/F/470. Report on financial position of AstraZeneca
- WORDS:
- 4500
- DATE:
- 2006
- PRICE:
- 49.99 GBP
The paper reports on AstraZeneca (AZN), a UK based pharmaceutical company, describing the companys structure, reviewing their recent deals, and conducting analysis of the pharmaceutical industry, the trends in the industry benchmarks ratios, and the analysis of AstraZenecas income statements, balance sheets, cash flow statements, etc. The companys benchmark ratios are compared to those of their main rivals. Conclusions are made about whether AstraZeneca is a profitable investment.
KEYWORDS: AstraZeneca, pharmaceutical, benchmark ratios,
S/B/96. The Competitive Position Analysis & Competitive Strategy for AstraZeneca PLC
- WORDS:
- 2500
- DATE:
- 2005
- PRICE:
- 29.99 GBP
This paper examines the competitive position of AstraZeneca PLC, identifying the key environmental influences and the main drivers for change through the use of PESTEL and SWOT analyses, and the key competitive forces through the use of Porters 5 Forces. This paper then provides recommendations of the strategic options available to AstraZeneca.
KEYWORDS: competitive, position, competitive, strategy, astrazeneca, plc,
P/F/247. Share movements of the Astrazeneca (AZN) pharmaceutical company
- WORDS:
- 1000
- DATE:
- 2004
- PRICE:
- 19.99 GBP
The paper examines the performance of Astrazeneca (AZN), an Anglo/Swedish pharmaceutical company, on the London Stock Exchange (LSE). A point by point analysis of its major share movements over a year's period is given. Conclusions are made about the variables that make the sector more volatile than the average.
KEYWORDS: f, share, movements, astrazeneca, azn, pharmaceutical, company,
P/M/366. Organisational Behaviour of AstraZeneca
- WORDS:
- 1000
- DATE:
- 2004
- PRICE:
- 19.99 GBP
The paper investigates the features of organisational behaviour reporting on the pharmaceutical industry and using the performance of the AstraZeneca Company as an example. The structure of the industry is outlined. Passive and active modes of organisational behaviour at the company are discussed.
KEYWORDS: organisational, behaviour, astrazeneca,
S/B/63. MBA Dissertation. Strategic Analysis of the Merger of Astra AB and Zeneca PLC
- WORDS:
- 15000
- DATE:
- 2004
- PRICE:
- 159.99 GBP
This dissertation looks at the 1999, cross-border merger, of Sweden's Astra AB and the UK's Zeneca PLC to form AstraZeneca PLC. The paper asks the question ?What motivated two successful companies, Astra AB and Zeneca PLC, to merge and was the merger successful in terms of shareholder wealth?. It examines the merger by assessing each organisation prior to merger, the strategic process and cultural impact of merging, the financial and cultural organisation post merger, concluding with an assessment of success. The paper is thoroughly researched, presents an in-depth bibliography and uses a good range of analytical tools and models
KEYWORDS: mba, dissertation, strategic, merger, astra, ab, zeneca, plc,
Subject Catalogue
- Dissertations and Proposals
- Analysis of Companies
- Analysis of Industries
- Architecture, Design and Technology
- Computing and Mathematics
- E-Commerce and E-Business
- Economics
- Education
- Engineering
- Fashion and Culture
- Finance and Accounting
- General Business
- History
- Hospitality and Tourism
- Human Resource Management
- International Relations
- Law
- Literature, Language and Theatre Studies
- Management and Organisational Behaviour
- Marketing
- Media, Music and Art
- Operations Management
- Philosophy
- Politics
- Psychology
- Science, Medicine and Nursing
- Sociology
GET OUR GooGLE TOOLBAR BUTTON
BOOK MARK US
WHAT OTHERS HAVE SAID
I have received the coursework and I consider the contents to be useful.Lee
